# US 11,406,691 B2 · AMH-INH-GNIH tri-expression gene vaccine of improving fecundity of animals, preparation method and application

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,406,691 B2
- Document ID: US11406691B2
- Status: Granted
- Kind: B2
- Application number: 17/025,486
- Filed: 2020-09-18
- Published: 2021-03-25
- Granted: 2022-08-09
- Earliest claimed: 2019-09-20
- Assignees: Huazhong Agricultural University
- Applicants: Huazhong Agricultural University
- Inventors: Liguo Yang; Jiaomei Tang; Qunli Zhou; Aixin Liang; Aizhen Guo
- Web page: https://patentgrep.com/patent/US11406691B2

## CPC

- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 39/0006: {Contraceptive vaccins; Vaccines against sex hormones}
- C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695)
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/70: {Multivalent vaccine}
- C07K 2319/00: Fusion polypeptide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides an AMH-INH-GNIH tri-expression gene vaccine capable of improving fecundity of animals and a preparation method of engineering strain thereof. The engineering strain was deposited in China Center for Type Culture Collection on Aug. 15, 2018, with deposit No.: CCTCC NO:M 2018544. When the engineering strain is used for direct immunization of animals or immunization of animals after being mixed with DNA vaccine adjuvant, the fecundity of the animals can be effectively improved. The tri-expression gene is a tri-expression non-resistant DNA plasmid of Mullerian duct resisting hormone, inhibin and gonadotropin release restraining hormone, which can be used for direct immunization of the animals through mucosa immunization to generate antibodies in the manner of being sprayed to noses, orally administered, blended into feeds and the like. Since the gene vaccine does not contain a resistant gene, exogenous antibiotics do not need to be introduced for screening, and antibiotic residues are not generated. Compared with other gene vaccines which need plasmid extraction and purification, high production cost and inconvenient intramuscular injection, and enable the animals to generate stress response, the gene vaccine of the invention is lower in production cost and more convenient to use, and is free from resistance and injection stress response.

## Claims

### Claim 1

An Anti-Müllerian hormone (AMH)-Inhibin (INH)- Gonadotropin release inhibiting hormone (GNIH) (AMH-INH-GNIH) tri-expression gene vaccine for improving the fecundity of animals, including a Tissue-type plasminogen activator- (TPA)-Hepatitis B surface antigen S gene (S)-Anti-Müllerian hormone (AMH)(tPA-SAMH) gene, a Tissue-type plasminogen activator-(TPA)-Hepatitis B surface antigen S gene (S)-Inhibin (INH) (tPA-SINH gene) and a Tissue-type plasminogen activator-(TPA)-Hepatitis B surface antigen S gene (S)-Gonadotropin release inhibiting hormone (GNIH) (tPA-SRFRP) gene in sequence.

### Claim 2 (depends on 1)

The tri-expression gene vaccine according to claim 1, wherein the gene sequence of tPA-SINH is shown in SEQ ID NO. 1, the gene sequence of tPA-SRFRP is shown in SEQ ID NO. 2 and the gene sequence of the tPA-SAMH is shown in SEQ ID NO.3.

### Claim 3 (depends on 1)

The tri-expression gene vaccine according to claim 1, wherein a 2A peptide is ligated between the tPA-SAMH gene and the tPA-SINH gene, a 2A′ peptide is ligated between the tPA-SINH gene and the tPA-SRFRP gene, the gene sequence of the 2A peptide is shown in SEQ ID NO.4; and the gene sequence of the 2A′ peptide is shown in SEQ ID NO.5.

### Claim 4 (depends on 1)

An engineering strain containing the AMH-INH-GNIH tri-expression gene vaccine according to claim 1.

### Claim 5 (depends on 4)

The engineering strain according to claim 4, wherein the engineering strain is deposited at the China Center for Type Culture Collection on Aug. 15, 2018, with a deposit number: CCTCC NO: M 2018544.

### Claim 6

A method for preparation of an Anti-Müllerian hormone (AMH)- Inhibin (INH)-Gonadotropin release inhibiting hormone (GNIH) (AMH-INH-GNIH) tri- expression gene vaccine for improving the fecundity of animals, including the following steps:
S1. Construction of dual expression plasmids PVAX-Tissue-type plasminogen activator-(TPA)- Hepatitis B surface antigen S gene (S)- Anti-Müllerian hormone (AMH)-2A peptides-Tissue- type plasminogen activator-(TPA)-Hepatitis B surface antigen S gene (S)-RFamide-related peptide (RFRP)-aspartate-semialdehyde dehydrogenase (asd) (PVAX-tPA-SAMH-2A-tPA-SRFRP-asd) and PVAX-Tissue-type plasminogen activator- (TPA)-Hepatitis B surface antigen S gene (S)-Inhibin (INH)-2A peptides-Tissue- type plasminogen activator-(TPA)-Hepatitis B surface antigen S gene (S)-RFamide-related peptide (RFRP)-aspartate-semialdehyde dehydrogenase (asd) (PVAX-tPA-SINH-2A′-tPA- SRFRP-asd);
S2. Enzyme digestion of the plasmids obtained in step S1 with Hind III and BamHI, respectively, followed by ligation to obtain a tri-expression plasmid PVAX-Tissue- type plasminogen activator-(TPA)-Hepatitis B surface antigen S gene (S)-Anti-Müllerian hormone (AMH)-2A peptides-Tissue-type plasminogen activator-(TPA)-Hepatitis B surface antigen S gene (S)-Inhibin (INH)-aspartate-semialdehyde dehydrogenase (asd) (PVAX-tPA-SAMH-2A-tPA-SINH-2A′-tPA-SRFRP-asd).

### Claim 7 (depends on 6)

The method according to claim 6, wherein the plasmid PVAX-tPA-SINH-2A′-tPA-SRFRP-asd is constructed according to the following method:
S1101, Using PVAX-tPA-SINH-asd as a template to amplify the tPA-SINH gene fragment; in which the gene sequence of the tPA-SINH PCR is shown in SEQ ID NO.1,
Using PVAX-tPA-SRFRP-asd as a template to amplify the tPA-SRFRP gene fragment; in which the gene sequence of the tPA-SRFRP gene fragment is shown in SEQ ID NO.2.
S1102 Enzyme digesting the PCR products of pVAX-asd and tPA-SRFRF with EcoRI and XhoI, followed by ligation to obtain a plasmid PVAX-tPA-SRFRP-asd;
S1103. Enzyme digesting the PCR products of PVAX-tPA-SRFRP-asd and tPA-SINH with BamH I and EcoRI, followed by ligation to obtain a plasmid PVAX-tPA-SINH-tPA-SRFRP-asd;
S1104. Enzyme digesting the plasmids PVAX-tPA-SINH-tPA-SRFRP-asd and PUC57-2A′-2A with EcoRI, followed by ligation to obtain a plasmid PVAX-tPA-SINH-2A′-tPA-SRFRP-asd; wherein the gene sequence of the 2A′ peptide is shown in SEQ ID NO.5.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the plasmid PVAX-tPA-SAMH-2A-tPA-SRFRP-asd is constructed according to the following method:
S1201. Enzyme digesting the PCR products of PVAX-tPA-SRFRP-asd and tPA-SAMH with Hind III and Kpn I, followed by ligation to obtain a plasmid PVAX-tPA-SAMH-tPA-SRFRP-asd; the gene sequence of the tPA-SAMH PCR product is shown in SEQ ID NO.3;
S1202. Enzyme digesting the plasmids PVAX-tPA-SAMH-tPA-SRFRP-asd and PUC57-2A′-2A with Kpn I and BamH I, followed by ligation to obtain a plasmid PVAX-tPA-SAMH-2A-tPA-SRFRP-asd; the gene sequence of the 2A peptide is shown in SEQ ID NO.4;
S1203. Enzyme digesting the plasmids PVAX-tPA-SAMH-2A-tPA-SRFRP-asd and PVAX-tPA-SINH-2A′-tPA-SRFRP-asd with Hind III and BamH I, followed by ligation to obtain a plasmid PVAX-tPA-SAMH-2A-tPA-SINH-2A′-tPA-SRFRP-asd.
